102 www.iakardiologie.cz PŘEHLEDOVÉ ČLÁNKY / REVIEW ARTICLES Kombinace beta-blokátoru a inhibitoru ACE v léčbě hypertenze a jejích komplikací 25. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. Jan 14 2020;41(3):407-477. doi:10.1093/ eurheartj/ehz425. 26. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol. Jan 1995;25(1):231-8. doi:10.1016/0735-1097(94)00345-q. 27. Bangalore S, Steg G, Deedwania P, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. Oct 3 2012;308(13):1340-9. doi:10.1001/jama.2012.12559. 28. Sabido M, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: A real-world evidence study. Pharmacol Res. Jan 2019;139:106-112. doi:10.1016/j. phrs.2018.10.031. 29. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta- -analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. May 19 2009;338:b1665. doi:10.1136/bmj.b1665. 30. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther. Apr 1999;13(2):123-6. doi:10.1023/a:1007784109255. 31. Ceconi C, Francolini G, Olivares A, et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. Dec 22 2007;577(1-3):1-6. doi:10.1016/j.ejphar.2007.07.061. 32. Fox KM, Investigators EUtOrocewPiscAd. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. Sep 6 2003;362(9386):782-8. doi:10.1016/s01406736(03)14286-9. 33. Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and beta-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. Dec 2015;170(6):1092-8. doi:10.1016/j.ahj.2015.08.018. 34. Brugts JJ, Bertrand M, Remme W, et al. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials. Cardiovasc Drugs Ther. Aug 2017;31(4):391-400. doi:10.1007/s10557-017-6747-9. 35. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. Sep 15 2022;387(11):967-977. doi:10.1056/NEJMoa2208275. INTERVENČNÍ A AKUTNÍ KARDIOLOGIE / Interv Akut Kardiol. 2024;23(2-3):96-102 / Využíváme systém CrossRef. S články můžete snadno pracovat díky jednoznačnému identi kátoru DOI. S NÁMI SE NEZTRATÍTE Časopis je indexován v těchto databázích: Scopus, Ebsco, Embase a Bibliographia medica čechoslovaca
RkJQdWJsaXNoZXIy NDA4Mjc=